-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70

Benzinga·10/21/2026 13:32:14
Diffusion vocale
Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $70.